Differences between Investing vs Trading
Differences between Investing vs Trading
Sanofi is one of the leading pharmaceutical and healthcare companies in France and western Europe. Sanofi’s primary goal is to conduct ground-breaking research and development, alongside the manufacture of prescription-based and over-the-counter pharmaceuticals. The company now specialises in seven core areas, seeking to provide therapeutic support across the following areas – diabetes, oncology, vaccines, thrombosis, cardiovascular, central nervous system and internal medicine.
In terms of its vaccine production, it is now considered one of the world’s biggest producers via its subsidiary Sanofi Pasteur. However, it did lag behind several other pharmaceutical giants in the rapid development of Covid-19 vaccines, namely AstraZeneca. Other firms such as Moderna and Novavax were also able to bring their products to the market faster, forcing Sanofi to admit defeat. However, it still has plenty of ambitious targets for the future.
Founded: 1973, Paris, France
Founders: Jean-René Sautier and Jean-François Dehecq
Headquarters: 54 Rue La Boetie, Paris, France 75008
Sanofi shares are publicly listed on the Euronext Paris under the ticker symbol (SAN). Sanofi is now a key component in the CAC 40 index, which comprises 40 of the most valuable listed companies in France. In the last five years, the Sanofi share price has risen over 22% between July 2017 and July 2022.
It reached an all-time high of $106.66 per share in April 2022, which was largely due to its ground-breaking collaboration with Regeneron for Dupixent, a treatment that’s on the verge of obtaining regulatory approval in the US to treat the rare skin condition known as prurigo nodularis.
Sanofi is one of the most prominent equities listed on the Euronext Paris exchange. As a world-leading pharmaceutical and healthcare company, it’s understandably one of the most valuable companies in the CAC 40 – France’s leading index of its 40 most significant businesses. With that comes a significant price tag for those wishing to invest in Sanofi shares.
However, with contracts for difference (CFD) trading, it’s possible to make money on the Sanofi share price without even physically owning their shares. CFD trading offers two benefits over investing in the underlying asset. Firstly, you can open a leveraged position, depositing a small percentage of the full value of your market exposure upfront. Just be mindful that leveraged positions can maximise losses as well as profits. Secondly, you can short-sell the asset to profit if you believe the price of Sanofi shares will fall.
|Swap long||[[ data.swapLong ]] points|
|Swap short||[[ data.swapShort ]] points|
|Spread min||[[ data.stats.minSpread ]]|
|Spread avg||[[ data.stats.avgSpread ]]|
|Min contract size||[[ data.minVolume ]]|
|Min step size||[[ data.stepVolume ]]|
|Commission and Swap||Commission and Swap|
|Trading Hours||Trading Hours|
* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.
The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.
Are Sanofi shares a good investment?
Sanofi shares have been on a tear in recent months, rising more than 30% since the start of 2019. It also has a strong financial position, with low debt levels and plenty of cash flow to support its operations. Given these factors, some investors may be wondering if Sanofi shares are a good trade at current levels.
However, there are a few risks to consider before buying Sanofi shares. First, the company is heavily reliant on its blockbuster diabetes drug Lantus, which generated sales of over €5 billion in 2018. Lantus faces generic competition in the near future, which could eat into Sanofi's profits.
Second, Sanofi is facing headwinds in its core French market. The company recently announced that it would be cutting 1,700 jobs in France as part of a restructuring plan. Investors should also be aware that Sanofi is a relatively large company, with a market capitalization of over €100 billion. This means that it may not be as easy for the stock to continue outperforming the broader market.
Who owns most Sanofi shares?
Sanofi's shares are mostly owned by French and American investors. The largest shareholder is the French government, which owns about 15% of Sanofi's shares. Other large shareholders include institutional investors such as BlackRock and Vanguard.BlackRock is the world's largest asset manager, with over $7 trillion in assets under management. Vanguard is the second largest asset manager, with over $4 trillion in assets under management. Together, these two firms own about 9% of Sanofi's shares.
Other large shareholders include mutual fund companies such as Fidelity and Capital Group, which each own about 3% of Sanofi's shares. Insurance companies such as AXA and Allianz also own significant stakes in Sanofi.
Do Sanofi shares pay dividends?
Yes, Sanofi shares pay dividends. The French pharmaceutical company has a long history of paying dividends, and the dividend payments have been increasing in recent years. The dividend payment in May 2020 was €3.20 per share and in May 2021 was €3.33 per share.
Why Trade [[data.name]]
Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.